Russian Journal of Woman and Child Health
ISSN 2618-8430 (Print), 2686-7184 (Online)

Rational choice of vaginal drug formulation

VAK

Scopus

E-libraryDOAJ

russian citation indexroad

ebscoULRICHS

cyberleninkagoogle-scholar

ВИНИТИРГБ

Open accessCrossrefAntiplagiat

RMJ.ru

License Creative Commons
All papers are licensed under a Creative Commons «Attribution» 4.0 License.


Impact factor - 1,090*

* Impact factor according to the SCIENCE INDEX 2022

DOI: 10.32364/2618-8430-2019-2-4-314-320

A.S. Dukhanin, O.E. Semioshina

Pirogov Russian National Research Medical University, Moscow, Russian Federation

This article addresses and supports the criteria for adequate choice of vaginal drug formulation. Comparative pharmaceutical and pharmacological properties of vaginal tablets and vaginal suppositories are reviewed. The effects of the shape and suppository base on vaginal drug formulation choice are discussed. Rational choice of vaginal medications in terms of drug formulation includes: correspondence of drug formulation to treatment goals (transvaginal drug delivery to the blood flow or topical treatment); coordination of pharmaceutical properties of drug formulation base with rapid and complete release of active components; effective combination of antimicrobial agents considering dosing frequency and course duration of the treatment with individual active components of fixed-dose combination; correspondence of drug formulation to the requirements of good adherence to treatment.

Case history illustrates that adequate anti-inflammatory therapy before the colposcopy is requ ired. Major indications to broad-spectrum topical combined vaginal medications are addressed. Choice criteria for these medications are specified.

Keywords: suppositories, vaginal tablets, adherence to treatment, active ingredients and excipients, complex topical medications, vaginal infections.

For citation: Dukhanin A.S., Semioshina O.E. Rational choice of vaginal drug formulation. Russian Journal of Woman and Child Health. 2019;2(4):314–320.




About the authors:

Aleksandr S. Dukhanin — MD, PhD, Professor, Professor of the Department of Molecular Pharmacology, ORCID iD 0000-0003-2433-7727;

Olga E. Semioshina — MD, PhD, Associate Professor of the Department of Obstetrics and Gynecology, ORCID iD 0000-0003-2938-3212.

Pirogov Russian National Research Medical University. 1, Ostrovityanov str., Moscow, 117437, Russian Federation.

Contact information: Olga E. Semioshina, e-mail: semiolya@mail.ru. Financial Disclosure: no authors have a financial or property interest in any material or method mentioned. There is no conflict of interests. Received 30.07.2019.


References
1. Katz D.F., Yuan A., Gao Y. Vaginal drug distribution modeling. Adv Drug Deliv Rev. 2015;92:2–13. DOI: org/10.1016/j.addr.2015.04.017.
2. Leyva-Gómez G., Del Prado-Audelo М.L., Ortega-Peña S. et al. Modifications in Vaginal Microbiota and Their Influence on Drug Release: Challenges and Opportunities. Pharmaceutics. 2019;11(217):1–18. DOI: org/10.3390/pharmaceutics11050217.
3. Kurian M., Rao B., Rao A.A.S. Effect of vaginal pH on efficacy of dinoprostone gel for labour induction. Int. J. Reprod. Contracept. Obstet. Gynecol. 2016;5:1196–1201. DOI: org/10.18203/2320-1770.ijrcog20160884.
4. Verstraelen H., Swidsinski A. The biofilm in bacterial vaginosis: Implications for epidemiology, diagnosis and treatment: 2018 update. Curr Opin Infect Dis. 2019;32:38–42. DOI: org/10.1097/QCO.0000000000000516.
5. Reiter S., Kellogg Spadt S. Bacterial vaginosis: A primer for clinicians. Postgrad Med. 2019;131:8–18. DOI: org/10.1080/00325481.2019.1546534.
6. Cook M.T., Brown M.B. Polymeric gels for intravaginal drug delivery. J Control Release. 2018;270:145–157. DOI: org/10.1016/j.jconrel.2017.12.004.
7. De Araújo Pereira R.R., Bruschi M.L. Vaginal mucoadhesive drug delivery systems. Drug Dev. Ind Pharm. 2012;38:643–652. DOI: org/10.3109/03639045.2011.623355.
8. Wilkinson E.M., Ilhan Z.E., Herbst-Kralovetz M.M. Microbiota — drug interactions: Impact on metabolism and efficacy of therapeutics. Maturitas. 2018;112:53–63. DOI: org/10.1016/j.maturitas.2018.03.012.
9. Caramella C.M., Rossi S., Ferrari F., Bonferoni М.C., Sandri G. Mucoadhesive and thermogelling systems for vaginal drug delivery. Adv Drug Deliv Rev. 2015;92:39–52. DOI: org/10.1016/j.addr.2015.02.001.
10. Grah A., Bouchemal K., Koffi A. et al. Formulation of mucoadhesive vaginal hydrogels insensitive to dilution with vaginal fluids. Eur J Pharm Biopharm. 2010;76:296–303. DOI: org/10.1016/j.ejpb.2010.07.004.
11. Palmeira-de-Oliveira R., Palmeira-de-Oliveira A., Martinez-de-Oliveira J. New strategies for local treatment of vaginal infections. Adv Drug Deliv Rev. 2015;92:105–122. DOI: org/10.1016/j.addr.2015.06.008.
12. Van den Berg J.J., Rosen R.K., Bregman D.E. et al. «Set it and Forget it»: Women’s Perceptions and Opinions of Long-Acting Topical Vaginal Gels. AIDS Behav. 2014;18:862–870. DOI: org/10.1007/s10461-013-0652-4.
13. Paul M., Leibovici L. Combination antimicrobial treatment versus monotherapy: the contribution of meta-analyses. Infect Dis Clin North Am. 2009;23(2):277–293. DOI: org/10.1016/j.idc.2009.01.004.
14. CDC 2015: STD Treatment Guidelines. Bacterial Vaginosis. (Electronic resource). URL: https://www.cdc.gov/std/tg2015/bv.htm. Access date: 20.07.2019. DOI: org/10.1111/j.1471-0528.2008.01780.x
15. Wong G.C., Li R.H., Wong T.S., Fan S.Y. The effect of topical lignocaine gel in pain relief for colposcopic assessment and biopsy: is it useful? BJOG. 2008;115(8):1057–1060.
16. Hiorth M., Nilsen S., Tho I. Bioadhesive mini-tablets for vaginal drug delivery. Pharmaceutics. 2014;6:494–511. DOI: 10.3390/pharmaceutics6030494.
17. Ashok V., Kumar R.M., Murali D., Chatterjee A. A Review on Vaginal Route as a systemic Drug Delivery. Critical Review in Pharmaceutical sciences. 2012;1(1):1–19.
18. Sahoo C.K., Nayak P.K., Sarangi D.K., Sahoo T.K. Intra Vaginal Drug Delivery System: An Overview. AJADD. 2013;1(1):43–55.
19. Ham A.S., Buckheit R.W. Designing and developing suppository formulations for anti-HIV drug delivery. Ther Deliv. 2017;8(9):805–817. DOI: org/10.4155/tde-2017-0056.
20. Zaveri T., Primrose R.J., Surapaneni L. et al. Firmness perception influences women’s preferences for vaginal suppositories. Pharmaceutics. 2014;6(3):512–529. DOI: org/10.3390/pharmaceutics6030512.
21. Li B., Zaveri T., Ziegler G.R., Hayes J.E. Shape of vaginal suppositories affects willingness-to-try and preference. Antiviral. Res. 2013;97(3):280–284. DOI: org/10.1016/j.antiviral.2012.12.024.
22. Общая фармакопейная статья ОФС.1.4.1.0013.15. Приказ Министерства здравоохранения РФ от 31 октября 2018 г. № 749. (Электронный ресурс). URL: http://www.garant.ru/products/ipo/prime/doc/71997630/. Дата обращения: 20.07.2019. [General pharmacopeia article OFS.1.4.1.0013.15. Order of the Ministry of Health of the Russian Federation of October 31, 2018 No. 749. (Electronic resource). URL: http://www.garant.ru/products/ipo/prime/doc/71997630/. Access date: 20.07.2019 (in Russ.)].
23. Zaveri T., Primrose R.J., Surapaneni L. et al. Firmness Perception Influences Women’s Preferences for Vaginal Suppositories. Pharmaceutics. 2014;6:512–529. DOI: org/10.3390/pharmaceutics6030512.
24. Choudhury A., Das S., Kar M. A review on novelty and potentiality of vaginal drug delivery. Int J Pharm Tech Res. 2011;3(2):1033–1044.
25. Ranjita S., Kamalinder S. In-vitro release of paracetamol from suppocire suppositories: role of additives. Malay J Pharm Sci. 2010;8(1):57–71.
26. Духанин А.С. Выбор системного противогрибкового препарата для лечения вагинального кандидоза: оригинальный или генерический препарат флуконазола? Медицинский совет. 2015;9:18–25. [Dukhanin A.S. Choosing a systemic antifungal drug for the treatment of vaginal candidiasis: original or generic fluconazole? Meditsinskiy sovet. 2015;9:18–25 (in Russ.)].
27. “International Association for Cervical Pathology and Colposcopy”, Rio De Janeiro; 2011. (Electronic resourse). URL: www.IFCPC.info/.com Access date: 20.07.2019.
28. The Bethesda System for Reporting Cervical Cytology. Ed. Nayar R., Wilbur D.N.Y. Springer; 2015.
29. Cobucci R., Maisonnette M., Macêdo E. et al. Paptest accuracy and severity of squamous intraepithelial lesion. Indian J Cancer, 2016;53(1):74–76. DOI: 10.4103/0019-509X.180825.
30. Blatt A.J., Kennedy R., Luff R.D. et al. Comparison of cervical cancer screening results among 256, 648 women in multiple clinical practices. Cancer Cytopathol. 2015;123(5):282–288. DOI: 10.1002/cncy.21544.
31. Royal College of Obstetricians and Gynaecologists. Progress in Cervical Screening in the UK. Scientific Impact Paper No.7 March 2016.
32. Saslow D., Solomon D., Lawson H.W. et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012;62(3):147–172. DOI: 10.3322/caac.21139.
33. Workowski K.A., Bolan G.A. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015;64(3):1–137. PMID: 26042815.
34. Макаров И.О., Гомберг М.А., Боровкова Е.И. и др. Бактериальный вагиноз: состояние изученности проблемы. Акушерство, гинекология, репродукция. 2013;7(4):20–24. [Makarov I.O., Gomberg M.A., Borovkova E.I. et al. Bacterial vaginosis: the state of knowledge of the problem. Akusherstvo, ginekologiya, reproduktsiya. 2013;7(4):20–24 (in Russ.)].
35. Радзинский В.Е., Ордиянц И.М. Двухэтапная терапия вагинальных инфекций. Результаты российского многоцентрового исследования «Сравнительная оценка различных схем лечения вагинальных бактериальных инфекций неспецифической этиологии (БИОС)». М.: Редакция журнала Status Praesens; 2012. [Radzinsky V.E., Ordiyants I.M. Two-stage therapy for vaginal infections. The results of the Russian multicenter study “Comparative evaluation of various treatment regimens for vaginal bacterial infections of non-specific etiology (BIOS)”. M.: Editorial office of Status Praesens; 2012 (in Russ.)].
36. Вагинальные инфекции вне и во время беременности. Взгляд гинеколога, дерматовенеролога и акушера. III конгресс «Дискуссионные вопросы современного акушерства», 2015. [Vaginal infections outside and during pregnancy. View of a gynecologist, dermatovenerologist and obstetrician. III Congress «Discussion issues of modern obstetrics», 2015 (in Russ.)].
37. Федеральные клинические рекомендации. Диагностика и лечение заболеваний, сопровождающихся патологическими выделениями из половых путей женщин. РОАГ. М.; 2019. [Federal clinical guidelines. Diagnosis and treatment of diseases accompanied by pathological discharge from the genital tract of women. ROAG. M .; 2019 (in Russ.)].
38. Guidelines Centers for Disease Control and Prevention, 2015.
39. Guidelines. International Union against Sexually Transmitted Infections, IJ of STD and AIDS. 2018;29:1258–1272. DOI: org/10.1177/0956462418785451.
40. Cagayan S., Bravo S.L., Fallarme A. Randomized, single-blind, one-centre trial comparing the efficacy, safety and acceptability of 3-day versus 7-day treatment of GYNOMAX® (150 mg tinidazole/100 mg tioconazole) vaginal ovules in vaginitis treatment. The 3rd Asia Pacific Congress on Controversies in Obstetrics Gynecology and Infertility. Beijing, China, 2009, November 12–15.



License Creative Commons
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Previous paper
Next paper

Register now and get access to useful services:
  • Загрузка полнотекстовых версий журналов (PDF)
  • Медицинские калькуляторы
  • Список избранных статей по Вашей специальности
  • Видеоконференции и многое другое

С нами уже 50 000 врачей из различных областей.
Присоединяйтесь!
[Error] 
Call to undefined function get_registration_form_description_popup() (0)
/home/c/cb72209/wchjournal/public_html/en/include/reg_form.php:89
#0: include
	/home/c/cb72209/wchjournal/public_html/bitrix/modules/main/classes/general/main.php:1419
#1: CAllMain->IncludeFile(string)
	/home/c/cb72209/wchjournal/public_html/local/templates/.default/include/cl-footer.php:217
#2: include_once(string)
	/home/c/cb72209/wchjournal/public_html/local/templates/cl_inner_sidebar_en/footer.php:11
#3: include_once(string)
	/home/c/cb72209/wchjournal/public_html/bitrix/modules/main/include/epilog_before.php:93
#4: require(string)
	/home/c/cb72209/wchjournal/public_html/bitrix/modules/main/include/epilog.php:2
#5: require_once(string)
	/home/c/cb72209/wchjournal/public_html/bitrix/footer.php:4
#6: require(string)
	/home/c/cb72209/wchjournal/public_html/en/articles/index.php:150
#7: include_once(string)
	/home/c/cb72209/wchjournal/public_html/bitrix/modules/main/include/urlrewrite.php:184
#8: include_once(string)
	/home/c/cb72209/wchjournal/public_html/bitrix/urlrewrite.php:2
----------